Head to head
Zai Lab vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: ZLAB · VRTX
ZLAB
Zai Lab
25.31-1.06%
1-year price shape — -23% over the period
Quant Rating D · 15/100
vs
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (67); Vertex Pharmaceuticals has done best over the past year (+23%); Vertex Pharmaceuticals earns the most per share.
| ZLAB | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 25.31 | 505.64 |
| Change today | -1.06% | +0.66% |
| 1-year return | -23.0% | +23.2% |
| Market cap | $2.84B | $128.16B |
| 52-week range | 15.96 – 31.85 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -14.89 | 29.45 |
| P/E percentile, own 5-yr range | 9th | 74th |
| P/B | 4.68 | 6.33 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -1.60 | 15.32 |
| Net profit (TTM) | $-179.63M | $3.88B |
| Revenue (TTM) | $449.61M | $12.59B |
| Revenue growth (YoY) | -3.3% | +12.5% |
| Gross margin | 56.5% | 86.0% |
| Operating margin | -57.4% | 37.9% |
| Net margin | -41.9% | 35.0% |
| Free cash flow (TTM) | $-162.52M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 78.5% | 97.2% |
| Insider activity (12mo) | 20 buy / 30 sell | 25 buy / 25 sell |
| Short interest (% of float) | 7.3% | 1.9% |
| Analyst consensus | 100% buy (3) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $39 (+55%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (15) | C (67) |
| Company | ||
| Employees | 1,784 | 6,400 |
| Founded | 2014 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.